Robyn J. Barst, Dunbar Ivy, J. Dingemanse
Apr 1, 2003
Citations
13
Influential Citations
340
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Bosentan, a dual endothelin‐receptor antagonist, is registered for the treatment of pulmonary arterial hypertension. Little is known about the effects of bosentan in children. This study was conducted to investigate the pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.